SpringerProtocols: Abstract: Development and Applications of Animal Models of Thrombosis

Development and Applications of Animal Models of Thrombosis

By: Ronald J. Shebuski², Larry R. Bush³, Alison Gagnon⁴, Liguo Chi⁵, Robert J. Leadley Jr.⁵

Abstract

Full Text

Download PDF (310K)

Of more than 2 million deaths in the United States each year (from all causes), nearly 1 million are caused by cardiovascular disease (CVD). CVD claims more lives each year than the next seven leading causes combined. The prevalence of CVD in the United States is indicated by the statistics: 50 million people with high blood pressure, 12.5 million people with coronary heart disease (CHD) (7.2 million with myocardial infarction [MI]; 6.3 million with angina pectoris), 4.4 million with stroke, 4.6 million with congestive heart failure, and 2.8 million suffering from other CVD diseases.

Affiliation(s): (2) CarePoint Medical Inc., Eden Prairie, MN
(3) Sepracor Inc., Marlborough, MA
(4) Incyte Genomics, Beverly, MA
(5) Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, MI

Book Title: Anticoagulants, Antiplatelets, and Thrombolytics

Series: Methods in Molecular Medicine | Volume: 93 | Pub. Date: Nov-03-2003 | Page Range: 175-219 | DOI: 10.1385/1-59259-658-4:175

Subject: Molecular Medicine

References

Download References

1.	Yeghiazarians, Y., Braunstein, J. B., Askari, A., and Stone, P. (2000) Unstable angina pectoris. N. Engl. J. Med. 342, 101–114.

2.	Anderson, H. V. and Willerson, J. T. (1994) Experimental models of thrombosis, in Thrombosis and Hemorrhage (Loscalzo, J. and Schafer, A. I., eds.), Blackwell Scientific, Boston, pp. 385–393.

3.	Badimon, L. (1997) Models to study thrombotic disorders. Thromb. Haemostasis 78, 667–671.

4.	Bush, L. R. and Shebuski, R. J. (1990) In vivo models of arterial thrombosis and thrombolysis. FASEB J. 4, 3087–3098.

5.	Chi, L., Rebello, S., and Lucchesi, B. R. (1999) In vivo models of thrombosis, in Handbook of Experimental Pharmacology, Vol. 132, Antithrombotics. Springer-Verlag, Berlin, pp. 101–127.

6.	Gold, H. K., Yasuda, T., Jang, I.-K., Guerrero, J. L., Fallon, J. T., Leinbach, R. C, et al. (1991) Animal models for arterial thrombolysis and prevention of reocclusion. Circulation 83, IV-26–IV-40.

7.	Leadley, R. J., Jr., Chi, L., Rebello, S. S., and Gagnon, A. (2000) Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. J. Pharmacol. Toxicol. Methods Mar-Apr;43(2), 101–116

8.	Bocan, T. M. A. (1998) Animal models of atherosclerosis and interpretation of drug intervention studies. Current Pharmaceutical Design 4, 37–52.

9.	Johnson, G J., Griggs, T. R., and Badimon, L. (1999) The utility of animal models in the preclinical study of interventions to prevent human coronary artery restenosis: analysis and recommendations. Thromb. Haemostasis 81, 835–843.

10.	Hunter, A. J., Green, A. R., and Cross, A. J. (1995) Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs? Trends Pharmacol. Sci. 16, 123–128.

11.	Virchow, R. (1856) I. Über die Verstopfung der Lungenarterie, in Gesammelte Abhandlungen zur wissenschaftlichen Medicin. Meidinger Sohn, Frankfurt, p. 221.

12.	Hara, T., Yokoyama, A., Morishima, Y, and Kunitada, S. (1995) Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb. Res. 80, 99–104.

13.	Leadley, R. J., Jr., Morgan, S., Bentley, R., Bostwick, J., Kasiewski, C, Chu, V., et al. (1999) Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa. J. Cardiovasc. Pharmacol. 34, 791–799.

14.	Heran, C, Morgan, S., Kasiewski, C, Bostwick, J., Bentley, R., Klein, S., et al. (2000) Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis. Eur. J. Pharmacol. 389, 201–207.

15.	Sato, K., Kawasaki, T., Hisamichi, N., Taniuchi, Y., Hirayama, F., Koshio, H., et al. (1998) Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Br. J. Pharmacol. 123, 92–96.

16.	Herbert, J. M., Bernat, A., Dol, F., Herault, J. P., Crepon, B., and Lormeau, J. C. (1996) DX 9065A, a novel, synthetic selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. The Journal of Pharmacology and Experimental Therapeutics 276, 1030–1038.

17.	Wiley, M. R., Weir, L. C, Briggs, S., Bryan, N. A., Buben, J., Campbell, C, et al. (2000) Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity. J. Med. Chem. 43, 883–899.

18.	Sato, K, Kawasaki, T., Taniuchi, Y., Hirayama, F., Koshio, H., and Matsumoto, Y (1997) YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. Eur. J. Pharmacol. 339, 141–146.

19.	Sato, K, Taniuchi, Y, Kawasaki, T, Hirayama, F., Koshio, H., and Matsumoto, Y (1998) Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats. Eur. J. Pharmacol. 347, 231–236.

20.	Morishima, Y, Tanabe, K., Terada, Y, Hara, T, and Kunitada, S. (1997) Antithrombotic and hemorrhagic effects of DX9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb. Haemostasis 78, 1366–1371.

21.	Wong, P. C, Crain, E. J., Nguan, O., Watson, C. A., and Racanelli, A. (1996) Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb. Res. 83, 117–126.

22.	Wong, A. G., Gunn, A. C, Ku, P., Hollenbach, S. J., and Sinha, U. (1997) Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arterio-venous thrombosis. Thromb. Haemostasis 77(6), 1143–1147.

23.	Yamazaki, M., Asakura, H., Aoshima, K, Saito, M., Jokaji, H., Uotani, C, et al. (1994) Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb. Haemostasis 72, 393–396.

24.	Sato, K, Kaku, S., Hirayama, F., Koshio, H., Matsumoto, Y, Kawasaki, T, et al. (1998b) Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time. Eur. J. Pharmacol. 352, 59–63.

25.	Wessler, S. (1952) Studies in intravascular coagulation. I. Coagulation changes in isolated venous segments. J. Clin. Invest. 31, 1011–1014.

26.	Seifert, D., Mitchell, T. J., Wang, Z., Knabb, R. M., Barbera, F., Reilley, T. M., et al. (1999) Prothrombin activation in rabbits. Thromb. Res. 93, 101–112.

27.	Vlasuk, G. P., Ramjit, D., Fujita, T., Dunwiddie, C. T., Nutt, E. M., Smith, D. E., et al. (1991) Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective Factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb. Haemostasis 65, 257–262.

28.	Bostwick, J. S., Bentley, R., Morgan, S., Brown, K., Chu, V., Ewing, W. R., et al. (1999) RPR120844, a novel, specific inhibitor of coagulation factor Xa, inhibits venous thrombus formation in the rabbit. Thromb. Haemostasis 81, 157–160.

29.	Quan, M. L., Liauw, A. Y., Ellis, C. D., Pruitt, J. R., Carini, D. J., Bostrom, L. L., et al. (1999a) Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1 J. Med. Chem. 42, 2752–2759.

30.	Quan, M. L., Ellis, C. D., Liauw, A. Y., Alexander, R. S., Knabb, R. M., Lam, G., et al. (1999b) Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2 J. Med. Chem. 42, 2760–2773.

31.	Wong, P. C, Quan, M. L., Crain, E. J., Watson, C. A., Wexler, R. R., and Knabb, R. M. (2000) Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J. Pharmacol. Exp. Ther. 292, 351–357.

32.	Sinha, U., Ku, P., Malinowski, J., Zhu, B. Y, Scarborough, R. M., Marlowe, C. K., et al. (2000) Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. Eur. J. Pharmacol. 395, 51–59.

33.	Shebuski, R. J., Storer, B. L., and Fujita, T. (1988) Effect of thromboxane synthetase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. Thromb. Res. 52, 381–392.

34.	Folts, J. D., Crowell, E. B., and Rowe, G G. (1976) Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 54, 365–370.

35.	Golino, P., Ragni, M., Cirillo, P., D’Andrea, D., Scognamiglio, A., Ravera, A., et al. (1998) Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model fo recurrent arterial thrombosis. Circ. Res. 82, 39–46.

36.	Aiken, J. W., Gorman, R. R., and Shebuski, R. J. (1979) Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins 17, 483–494.

37.	Uchida, Y, Yoshimoto, N., and Murao, S. (1975) Cyclic reductions in coronary blood pressure and flow induced by coronary artery constriction. Jpn. Heart J. 16, 454–464.

38.	Folts, J. D., Gallagher, K., and Rowe, G. G. (1982) Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation. Circulation 65, 248–255.

39.	Aiken, J. W., Shebuski, R. J., Miller, O. V., and Gorman, R. R. (1981) Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. J. Pharmacol. Exp. Ther. 219, 299–308.

40.	Bush, L. R., Campbell, W. B., Buja, L. M., Tilton, G. D., and Willerson, J. T. (1984) Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in coronary blood flow in stenosed canine coronary arteries. Circulation 69, 1161–1170.

41.	Bush, L. R., Holahan, M. A., Kanovsky, S. M., Mellott, M. J., Garsky, V. J. and Gould, R. J. (1989) Antithrombotic profile of echistatin, a snake venom peptide and platelet fibrinogen receptor antagonist in the dog. Circulation 80, 11–23.

42.	Shebuski, R. J., Ramjit, D. R., Bencen, G. H., and Polokoff, M. A. (1989) Characterization and platelet inhibitory activity of bitistatin, a potent RGD-containing peptide from the venom of the viper, Bitis arietans. J. Biol. Chem. 264, 21,550–21,556.

43.	Bush, L. R. and Patrick, D. (1986) The role of the endothelium in arterial thrombosis and the influence of antithrombotic therapy. Drug Dev. Res. 7, 319–340.

44.	Golino, P., Ashton, J. H., Buja, L. M., Rosolowsky, M., Taylor, A. L., McNatt, J., et al. (1989) Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A₂ and serotonin are possible mediators. Circulation 79, 154–166.

45.	Bush, L. R., Campbell, W. B., Kern, K., Tilton, G. D., Apprill, P., Ashton, J., et al. (1984) The effects of alpha₂-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ. Res. 55, 642–652.

46.	Bennett, J. S. and Vilaire, G. (1979) Exposure of platelet fibrinogen receptors by ADP and epinephrine. J. Clin. Invest. 64, 1393–1401.

47.	Coller, B. S. and Scudder, L. E. (1985) Inhibition of dog platelet function by in vivo infusion of F(ab′)₂ fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood 66, 1456–1459.

48.	Shebuski, R. J., Berry, D. E., Bennett, D. B., Romoff, T, Storer, B. L., Au, F., and Samanen, J. (1989) Demonstration of Ac-ArgGly-Asp-Ser-NH₂ as an antiaggregatory agent in the dog by intracoronary administration. Thromb. Haemostasis 61, 183–188.

49.	Eidt, J. E, Allison, P., Noble, S., Ashton, J., Golino, P, McNatt, J., et al. (1989) Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J. Clin. Invest. 84, 18–27.

50.	Smith, J. M. and Shebuski, R. J. (1988) Lack of an inhibitory effect of tissue plasminogen activator (tPA) on platelet aggregation in vivo. FASEB J. 2, A1164.

51.	Al-Wathiqui, M. H., Hartman, J. C, Brooks, H. L., Gross, G J., and Warltier, D. C. (1988) Cyclical carotid artery flow reduction in conscious dogs: effect of a new thromboxane receptor antagonist. Am. Heart J. 116, 1482–1487.

52.	Gallagher, K. P., Folts, J. D., and Rowe, G. G. (1978) Comparison of coronary arteriograms with direct measurements of stenosed coronary arteries in dogs. Am. Heart J. 95, 338–347.

53.	Schumacher, W. A., Heran, C. L., Goldenberg, H. J., Harris, D. N., and Ogletree, M. L. (1989) Magnitude of thromboxane receptor antagonism necessary for antithrombotic activity in monkeys. Am. J. Physiol. 256, H726–H734.

54.	Coller, B. S., Folts, J. D., Scudder, L. E., and Smith, S. R. (1986) Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 68, 783–786.

55.	Eidt, J. F., Ashton, J., Golino, P, McNatt, J., Buja, L. M. and Willerson, J. T. (1989) Treadmill exercise promotes cyclic alterations in coronary blood flow in dogs with coronary artery stenoses and endothelial injury. J. Clin. Invest. 84, 517–526.

56.	O’Neill, W. W., Topol, E. J., and Pitt, B. (1988) Coronary thrombolysis for evolving myocardial infarction. Prog. Cardiovasc. Dis. 30, 465–483.

57.	Blair, E., Nygren, E., and Cowley, R. A. (1964) A spiral wire technique for producing gradually occlusive coronary thrombosis. J. Thorac. Cardiovasc. Surg. 48, 476–485.

58.	Kordenat, R. K. and Kezdi, P. (1972) Experimental intracoronary thrombosis and selective in situ lysis by catheter technique. Am. J. Heart 83, 360–364.

59.	Romson, J. L., Haack, D. W., and Lucchesi, B. R. (1980) Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb. Res. 17, 841–853.

60.	Bergmann, S. R., Fox, K. A. A., Ter-Pogossian, M. M., Sobel, B. E., and Collen, D. (1983) Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science 220, 1181–1183.

61.	Bush, L. R., Mellott, M. J., Kanovsky, S. M., Holahan, M. A., and Patrick, D. H. (1989) A model of femoral artery thrombolysis in dogs. Fibrinolysis 3, 107–114.

62.	Marsh-Leidy, E., Stern, A. M., Friedman, P A., and Bush, L. R. (1990) Enhanced thrombolysis by a factor XIIIa inhibitor in a rabbit model of femoral artery thrombosis. Thromb. Res. 59, 15–26.

63.	Golino, P, Ashton, J. H., Glas-Greenwalt, P, McNatt, J., Buja, L. M., and Willerson, J. T. (1988) Mediation of reocclusion by thromboxane A₂ and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 77, 678–684.

64.	Bergmann, S. R., Lerch, R. A., Ludbrook, P A., Welch, M. J., Ter-Pogossian, M. M., and Sobel, B. E. (1982) Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am. J. Med. 73, 573–581.

65.	Van der Werf, F., Jang, I. K., and Cohen, D. (1987) Thrombolysis with recombinant human single chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis. J. Cardiovasc. Pharmacol. 9, 91–93.

66.	Mellott, M. J., Connolly, T M., York, S. J., and Bush, L. R. (1990) Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA induced thrombolysis in a canine model of femoral arterial thrombolysis. Thromb. Haemostasis 64, 526–534.

67.	Gold, H. K., Fallon, J. T, Yasuda, T, Leinbach, R. C, Khaw, B. A., Newell, J. B., et al. (1984) Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation 70, 700–707.

68.	Collen, D., Stassen, J. M., and Verstraete, M. (1983) Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. J. Clin. Invest. 71, 368–376.

69.	Kopia, G. A., Kopaciewicz, L. J., and Ruffolo, R. R. (1988) Coronary thrombolysis with intravenous streptokinase in the anesthetized dog: a dose-response study. J. Pharmacol. Exp. Ther. 244, 956–962.

70.	Gold, H. K., Coller, B. S., Yasuda, T., Saito, T., Fallon, J. T., Guerrero, J. L., et al. (1988) Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet Gp IIb/IIIa antibody in a canine preparation. Circulation 77, 670–677.

71.	Gold, H. K., Leinbach, R. C, Garabedian, H. D., Yasuda, T., Johns, J. A., Grossbard, E. B., et al. (1986) Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 73, 347–352.

72.	Goldberg, R. K., Levine, S., and Fenster, P. E. (1985) Management of patients after thrombolytic therapy for acute myocardial infarction. Clin. Cardiol. 8, 455–459.

73.	Coller, B. S., Peerschke, E. I., Scudder, L. E., and Sullivan, C. A. (1983) A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J. Clin. Invest. 72, 325–338.

74.	Yasuda, T., Gold, H. K., Fallon, J. T., Leinbach, R. C, Guerrero, J. L., Scudder, L. E., et al. (1988) Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue type plasminogen activator. J. Clin. Invest. 81, 1284–1291.

75.	Salazar, A. E. (1961) Experimental myocardial infarction, induction of coronary thrombosis in the intact closed-chest dog. Circ. Res. 9, 135–136.

76.	Romson, J. L., Haack, D. W., and Lucchesi, B. R. (1980) Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb. Res. 17, 841–853.

77.	Schumacher, W. A., Lee, E. C, and Lucchesi, B. R. (1985) Augmentation of strep-tokinase-induced thrombolysis by heparin and prostacyclin. J. Cardiovasc. Pharmacol. 7, 739–746.

78.	Benedict, C. R., Matthew, B., Rex, K. A., Cartwright, J., Jr., and Sordahl, L. A. (1986) Correlation of plasma serotonin changes with platelet aggregation in an in vivo dog model of spontaneous occlusive coronary thrombus formation. Circ. Res. 58, 58–67.

79.	Van der Giessen, W. J., Harmsen, E., de Tombe, P. P., Hugenholtz, P. G, and Verdouw, P D. (1988) coronary thrombolysis with and without nifedipine in pigs. Basic Res. Cardiol. 83, 258–267

80.	Shea, M. J., Driscoll, E. M., Romson, J. L., Pitt, B., and Lucchesi, B. R. (1984) Effects of OKY 1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog. Eur. J. Pharmacol. 105, 285–291.

81.	Simpson, P. J., Smith, J. B., Jr., Rosenthal, G., and Lucchesi, B. R. (1986) Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury. J. Pharmacol. Exp. Ther. 238, 497–501.

82.	Hook, B. G., Schumacher, W. A., Lee, D. L., Jolly, S. R., and Lucchesi, B. R. (1985) Experimental coronary artery thrombosis in the absence of thromboxane A₂ synthesis: evidence for alternate pathways for coronary thrombosis. J. Cardiovasc. Pharmacol. 7, 174–181.

83.	Schumacher, W. A. and Lucchesi, B. R. (1983) Effect of the thromboxane synthetase inhibitor UK 37,248 (Dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity. J. Pharmacol. Exp. Ther. 227, 790–796.

84.	FitzGerald, D. J., Fragetta, J., and FitzGerald, G. A. (1988) Prostaglandin endoperoxides modulate the response to thromboxane synthetase inhibition during coronary thrombosis. J. Clin. Invest. 82, 1708–1713.

85.	Mickelson, J. K., Simpson, P J., and Lucchesi, B. R. (1989) Antiplatelet monoclonal F(ab)₂ antibody directed against the platelet. GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J. Mol. Cell. Cardiol. 21, 393–405.

86.	Kawasaki, T., Sato, K., Sakai, Y., Hirayama, F, Koshio, H., Taniuchi, Y., et al. (1998) Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb. Haemostasis 79, 410–416.

87.	Shebuski, R. J., Smith, J. M., Storer, B. L., Granett, J. R., and Bugelski, P. J. (1988) Influence of selective endoperoxide/thromboxane A₂ receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog. J. Pharmacol. Exp. Ther. 246, 790–796.

88.	Van der Giessen, W. J., Zijlstra, F J., Berk, L., and Verdouw, P D. (1988) The effect of the thromboxane receptor antagonist BM 13,177 on experimentally induced coronary artery thrombosis in the pig. Eur. J. Pharmacol. 147, 241–248.

89.	Patterson, E., Eller, B. T., Abrams, G. D., Vasiliades, J., and Lucchesi, B. R. (1983) Ventricular fibrillation in a conscious canine preparation of sudden coronary death. Prevention by short-and long-term amiodarone administration. Circulation 68, 857–864.

90.	Rebello, S. S., Blank, H. S., Rote, W. E., Vlasuk, G. P., and Lucchesi, B. R. (1997) Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J. Pharmacol. Exp. Ther. 283, 91–99.

91.	Sitko, G. R., Ramjit, D. R., Stabilito, I. I., Lehman, D., Lynch, J. J., and Vlasuk, G. P. (1992) Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective Factor Xa inhibitor, tick anticoagulant peptide. Circulation 85, 805–815.

92.	Lynch, J. J., Jr., Sitko, G R., Mellott, M. J., Nutt, E. M., Lehman, E. D., Friedman, P. A., et al. (1994) Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc. Res. 28, 78–85.

93.	Nicolini, F. A., Lee, P., Rios, G., Kottke-Marchant, K., and Topol, E. J. (1994) Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 89, 1802–1809.

94.	Lefkovits, J., Malycky, J. L., Rao, J. S., Hart, C. E., Plow, E. F., Topol, E. J., et al. (1996) Selective inhibition of Factor Xa is more efficient than Factor VIIa-Tissue Factor complex at facilitating coronary thrombolysis in the canine model. J. Am. Coll. Cardiol. 28, 1858–1865.

95.	Waxman, L., Smith, D. E., Arcuri, K. E., and Vlasuk, G. P. (1990) Tick anticoagulant peptide is a novel inhibitor of blood coagulation factor Xa. Science 248, 593–596.

96.	Wysokinski, W., McBane, R., Chesebro, J. H., and Owen, W. G. (1996) Reversibility of platelet thrombosis in vivo. Thromb. Haemostasis 76, 1108–1113.

97.	Badimon, L. and Badimon, J. J. (1989) Mechanism of arterial thrombosis in non-parallel streamlines: Platelet thrombi grow on the apex of stenotic severely injured vessel wall. J. Clin. Investig. 84, 1134–1144.

98.	Dangas, G., Badimon, J. J., Coller, B. S., Fallon, J. T, Sharma, S. K., Hayes, R. M., et al. (1998) Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition. Arterioscler. Thromb. Vase. Biol. 18, 1342–1349.

99.	Ørvim, U., Brastad, R. M., Vlasuk, G P., and Sakariassen, K. S. (1995) Effect of selective Factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler. Thromb. Vase. Biol. 15, 2188–2194.

100.	Todd, M. E., McDevitt, E. L., and Goldsmith, E. I. (1972) Blood-clotting mechanisms of nonhuman primates: choice of the baboon model to simulate man. J. Med. Primatol. 1, 132–141.

101.	Harker, L. A., Kelly, A. B., and Hanson, S. R. (1991) Experimental arterial thrombosis in nonhuman primates. Circulation 83, IV-41–IV-55.

102.	Cadroy, Y., Hanson, S. R., and Harker, L. A. (1993) Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb. Haemostasis 70, 631–635.

103.	Yokoyama, T, Kelly, A. B., Marzec, U. M., Hanson, S. R., Kunitada, S., and Harker, L. A. (1995) Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 92, 485–491.

104.	Vuillemenot, A., Schiele, F, Meneveau, N., Claudel, S., Donat, F, Fontecave, S., et al. (1999) Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent—A pilot study in the setting of coronary angioplasty. Thromb. Haemostasis 81, 214–220.

105.	Murayama, N., Tanaka, M., Kunitada, S., Yamada, H., Inoue, T, and Terada, Y (1999) Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin. Pharmacol. Ther. 66, 258–264.

106.	Kotze, H. F., Lamprecht, S., Badenhorst, P. N., Roodt, J. P., and van Wyk, V. (1997) Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons. Thromb. Haemostasis 77, 1137–1142.

107.	Eppehimer, M. J. and Schaub, R. G. (2000) P-selectin-dependent inhibition of thrombosis during venous stasis. Arterioscler. Thromb. Vase. Biol. 20(11), 2483–2488.

108.	Wakefield, T. W., Strieter, R. M., Schaub, R., Myers, D. D., Prince, M. R., Wrobleski, S. K., et al. (2000) Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy. J. Vase. Surg. 31(2), 309–324.

109.	Myers, D. D., Jr., Schaub, R., Wrobleski, S. K., Londy, F. J., 3rd, Fex, B. A., Chapman, A. M., et al. (2001) P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb. Haemostasis 85(3), 423–429.

110.	Schumacher, W. A., Heran, C. L., and Steinbacher, T. E. (1996) Low-molecular-weight heparin (Fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. J. Card. Pharmacol. 28, 19–25.

111.	Stieg, P. E. and Kase, C. S. (1998) Intracranial hemorrhage: diagnosis and emergency management. Neurol. Clin. 16, 373–390.

112.	Sloan, M. A. and Gore, J. M. (1992) Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: a risk-benefit analysis. Am. J. Cardiol. 69, 21A–38A.

113.	Bernardi, M. M., Califf, R. M., Kleiman, N., Ellis, S. G., and Topol, E. J. (1993) Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. Am. J. Cardiol. 72, 1121–1125.

114.	Bick, R. L. (1995) Laboratory evaluation of platelet dysfunction. Clin. Lab. Med. 15, 1–38.

115.	Rodgers, R. P. C. and Levin, J. (1990) A critical reappraisal of the bleeding time. Sem. Thromb. Hemost. 16, 1–20.

116.	Antman, E. M. and TIMI 9B Investigators (1996) Hirudin in acute myocardial infarction: Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 4, 911–921.

117.	Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb/IIIa Investigators (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N. Engl. J. Med. 335, 775–782.

118.	Cox, D., Motoyama, Y., Seki, J., Aoki, T, Dohi, M., and Yoshida, K. (1992) Pentamadine: a non-peptide GPIIb/IIIa antagonist-in vitro studies on platelets from humans and other species. Thromb. Haemostasis 68, 731–736.

119.	Bostwick, J. S., Kasiewski, C. J., Chu, V., Klein, S. I., Sabatino, R. D., Perrone, M. H., et al. (1996) Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist. Thromb. Res. 82, 495–507.

120.	Cook, N. S., Zerwes, H.-G., Tapparelli, C, Powling, M., Singh, J., Metternich, R., et al. (1993) Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists. Thromb. Haemostasis 70, 531–539.

121.	Panzer-Knodle, S., Taite, B. B., Mehrotra, D. V., Nicholson, N. S., and Feigen, L. P. (1993) Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation. J. Pharmacol. Toxicol. Methods 30, 47–53.

122.	Cook, J. J., Holahan, M. A., Lyle, E. A., Ramjit, D. R., Sitko, G. R., Stranieri, M. T., et al. (1996) Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J. Pharmacol. Exp. Ther. 278, 62–73.

123.	Tidwell, R. R., Webster, W. P., Shaver, S. R., and Geratz, J. D. (1980) Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitors versus thrombin inhibitors. Thromb. Res. 19, 339–349.

124.	Nutt, E. M., Jain, D., Lenny, A. B., Schaffer, L., Siegl, P. K., and Dunwiddie, C. T. (1991) Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa. Arch. Biochem. Biophys. 285, 37–44.

125.	Taniuchi, Y., Sakai, Y., Hisamichi, N., Kayama, M., Mano, Y, Sato, K., et al. (1998) Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human Factor Xa. Thromb. Haemostasis 79, 543–548.

126.	Kararli, T. T. (1995) Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 16, 351–380.

127.	Sanderson, P. E. J., Cutrona, K. J., Dorsey, B. D., Dyer, D. L., McDonough, C. M., Naylor-Olsen, A. M., et al. (1998) L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorg. Med. Chem. Lett. 8, 817–822.

128.	Carmeliet, P. and Collen, D. (1999) New developments in the molecular biology of coagulation and fibrinolysis, in Handbook of Experimental Pharmacology, Vol. 132, Antithrombotics. Springer-Verlag, Berlin, pp. 41–76.

129.	Pearson, J. M. and Ginsburg, D. (1999) Use of transgenic mice in the study of thrombosis and hemostasis, in Handbook of Experimental Pharmacology, Vol. 132, Antithrombotics. Springer-Verlag, Berlin, pp. 157–174.

130.	Bi, L., Sarkar, R., Naas, T., Lawler, A. M., Pain, J., Shumaker, S. L., et al. (1996) Further characterization of Factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 88, 3446–3450.

131.	Wang, L., Zoppè, M., Hackeng, T. M., Griffin, J. H., and Lee, K.-F (1997) A factor IX-deficient mouse model for hemophilia B gene therapy. Proc. Natl. Acad. Sci. USA 94, 11,563–11,566.

132.	Denis, C, Methia, N., Frenette, P. S., Rayburn, H., Ullman-Cullere, M., Hynes, R. O., et al. (1998) A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc. Natl. Acad. Sci. USA 95, 9524–9529.

133.	Hodivala-Dilke, K. M., McHugh, K. P., Tsakiris, D. A., Rayburn, H., Crowley, D., Ullman-Culleré, M., et al. (1999) β₃-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 103, 229–238.

134.	Offermanns, S., Toombs, C. F., Hu, Y.-H., and Simon, M. I. (1997) Defective platelet activation in Gα_q-deficient mice. Nature 389, 183–186.

135.	Law, D. A., DeGuzman, F. R., Heiser, P., Ministri-Madrid, K., Killeen, N., and Phillips, D. R. (1999) Integrin cytoplasmic tyrosine motif is required for outside-in αllbβ3 signalling and platelet function. Nature 401, 808–811.

136.	Thomas, D. W., Mannon, R. B., Mannon, P. J., Latour, A., Oliver, J. A., Hoffman, M., et al. (1998) Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A₂. J. Clin. Invest. 102, 1994–2001.

137.	Subramaniam, M., Frenette, P. S., Saffaripour, S., Johnson, R. C, Hynes, R. O., and Wagner, D. D. (1996) Defects in hemostasis in P-selectin-deficient mice. Blood 87, 1238–1242.

138.	Leon, C, Hechler, B., Freund, M., Eckly, A., Vial, C, Ohlmann, P., et al. (1999) Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y₁ receptor-null mice. J. Clin. Invest. 104, 1731–1737.

139.	Kahn, M. L., Zheng, Y.-W., Huang, W., Bigornia, V., Zeng, D., Moff, S., et al. (1998) A dual thrombin receptor system for platelet activation. Nature 394, 690–694.

140.	Bugge, T. H., Suh, T. T., Flick, M. J., Daugherty, C. C., Romer, J., Solberg, H., et al. (1995) The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Client. 270, 16,886–16,894.

141.	Ploplis, V. A., Carmeliet, P., Vazirzadeh, S., Van Vlaenderen, I., Moons, L., Plow, E. F., et al. (1995) Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 92, 2585–2593.

142.	Carmeliet, P., Schoonjans, L., Kieckens, L., Ream, B., Degen, J., Bronson, R., et al. (1994) Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368, 419–424.

143.	Christie, P. D., Edelberg, J. M., Picard, M. H., Foulkes, A. S., Mamuya, W., Weiler-Guettler, H., et al. (1999) A murine model of myocardial thrombosis. J. Clin. Invest. 104, 533–539.

144.	Carmeliet, P., Stassen, J. M., Schoonjans, L., Ream, B., van den Oord, J. J., De Mol, M., et al. (1993) Plasminogen activator inhibitor-1 gene-deficient mice. J. Clin. Invest. 92, 2756–2760.

145.	Bugge, T H., Xiao, Q., Kombrinck, K. W., Flick, M. J., Holmback, K., Danton, M. J. S., et al. (1996) Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc. Natl. Acad. Sci. USA 93, 6258–6263.

146.	Toomey, J. R., Kratzer, K. E., Lasky, N. M., Stanton, J. J., and Broze, G. J., Jr. (1996) Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 88, 1583–1587.

147.	Carmeliet, P., Mackman, N., Moons, L., Luther, T., Gressens, P., Van Vlaenderen, I., et al. (1996) Role of tissue factor in embryonic blood vessel development. Nature 383, 73–75.

148.	Huang, Z.-F., Higuchi, D., Lasky, N., and Broze, G J., Jr. (1997) Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 90, 944–951.

149.	Healy, A. M., Rayburn, H. B., Rosenberg, R. D., and Weiler, H. (1995) Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc. Natl. Acad. Sci. USA 92, 850–854.

150.	Connolly, A. J., Ishihara, H., Kahn, M. L., Farese, R. V., Jr., and Coughlin, S. R. (1996) Role of the thrombin receptor in development and evidence for a second receptor. Nature 381, 516–519.

151.	Cui, J., O’Shea, K. S., Purkayastha, A., Saunders, T L., and Ginsburg, D. (1996) Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 384, 66–68.

152.	Lin, H.-F, Maeda, N., Sithies, O., Straight, D. L., and Stafford, D. W. (1997) A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 90, 3962–3966.

153.	Kung, J., Hagstrom, J., Cass, D., Tai, S., Lin, H. F, Stafford, D. W., and High, K. A. (1998) Human FIX corrects bleeding diathesis of mice with hemophilia B. Blood 91, 784–790.

154.	Evans, J. P., Brinkhous, K. M., Brayer, G. D., Reisner, H. M., and High, K. A. (1989) Canine hemophilia B resulting from a point mutation with unusual consequences. Proc. Natl. Acad. Sci. USA 86, 10,095–10,099.

155.	Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., et al. (1999) Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 5, 56–63.

156.	Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., et al. (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients with an AAV vector. Nat. Genet. 24, 257–261.

157.	Waugh, J. M., Yuksel, E., Li, J., Kuo, M. D., Kattash, M., Saxena, R., et al. (1999) Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ. Res. 84, 84–92.

158.	Waugh, J. M., Kattash, M., Li, J., Yuksel, E., Kuo, M. D., Lussier, M., et al. (1999) Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc. Natl. Acad. Sci. U.S.A. 96(3), 1065–1070.

159.	Zoldhelyi, P., McNatt, J., Shelat, H. S., Yamamoto, Y., Chen, Z. Q., and Willerson, J. T. (2000) Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 101, 289–295.

160.	Vassalli, G. and Dichek, D. A. (1997) Gene therapy for arterial thrombosis. Cardiovasc. Res. 35, 459–469.

Comments (Loading...)

Post comment/View all comments